Recent News Did you know 1 in 4 adults older than 25 will experience a stroke in their lifetime - it is a huge and daunting problem that many of us will have to face in our lives. The global stroke treatment market is expected to reach a value of $15B by 2027.
AGN.c AGNPF is a Canadian clinical stage pharmaceutical development company who just completed the second cohort in its escalating dose Phase 1 clinical study of an intravenous formulation of AP-188 (DMT) for stroke and have been approved to move forward.
With this approval they continue to be a leader in the space and are pushing the cutting edge of both DMT applications and stroke research. Findings from the study have the potential to be groundbreaking.
https://www.algernonpharmaceuticals.com/news-media/news-releases/detail/180/algernon-neuroscience-announces-successful-dosing-of-2nd